Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06945861
Recruiting Observational

Immunological Aspect of Thrombotic Thrombocytopenic Purpura (TTP)

NCT06945861 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Rouen
Phase
Observational
Started
2023-05-11
Last updated
2026-05-04

Condition(s) studied

Thrombotic Thrombocytopenic Purpura (TTP)

Study summary

The general objective of the proposed project is to characterise phenotypically and functionally ADAMTS13-specific memory B lymphocytes and autoreactive T lymphocytes, in particular follicular helper T lymphocytes, in the acute phase of the disease, but also during its progression after treatment. The aim is to highlight their contribution to the initial pathogenic process, their evolution under treatment, and also their involvement in patients who are refractory to immunosuppressive therapies and during relapses. The aim of this project is to identify early phenotypic or functional parameters that are predictive of relapse and that can be used for personalised optimisation of treatment to maintain remission.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * age over 18 * patients with TTP at any stage of diagnosis (acute phase, lasting remission or not, relapse) * patients undergoing internal medicine at Rouen University Hospital * people who have read and understood the information letter * membership of a social security scheme Exclusion Criteria: \- a person deprived of liberty by an administrative or judicial decision or a person placed under court protection/guardianship or guardianship

Primary outcome measure(s)

  • Identifying the presence of circulating autoreactive T lymphocytes — At enrollment visit, Month 3, Month 6 and month 12
    Identifying the presence of circulating autoreactive T lymphocytes in patients with TTP using the ELISPOT technique (Demonstration of spots indicating the presence of gamma interferon-producing T lymphocytes)
  • Identify the presence of circulating autoreactive B lymphocytes — At enrollment visit, Month 3, Month 6 and month 12
    Identifying the presence of circulating autoreactive B lymphocytes in patients with TTP using the ELISPOT technique (Demonstration of IL-21 spots and specific B lymphocytes producing anti-ADAMTS13 antibodies in response to the ADAMTS13 antigen)

Trial sites (1)

FacilityCityRegionStatus
University Rouen Hospital, Rouen France Recruiting

More University Hospital, Rouen trials in France

Impact of a Personalized Medication Plan on Duration of Treatment With Potent Opioids in Acute Non-cancer Musculoskeletal Pain. Recruiting
Cohort for Monitoring Patients With Venous Thromboembolic Disease Recruiting
Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus Recruiting
Use of Omics Methods to Classify Variations of Uncertain Significance and Improve Diagnosis of Neurogenetic Diseases Recruiting
Effectiveness of an Immune-guided Cytomegalovirus Infection Preventive Strategy Compared to a Universal Prophylactic Strategy in Renal Transplant Patients Recruiting

Other trials for the same condition

Retrospective Epidemiological Study of Patients in the National Cohort of the French TMA Center Recruiting
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06945861 on ClinicalTrials.gov ↗ ← All trials in France